In this capacity menin is a regulator of expression of the cyclin-dependent-kinase inhibitors p18INK4C and p27Kip1; furthermore, menin serves as a co-activator of estrogen receptor mediated ...
NOVEL research has uncovered how a gut receptor, free fatty acid receptor 4 (Ffar4), influences ... vulgatus through microbiota transplantation reduced sugar consumption in knockout mice, underscoring ...
Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease. PCOS patients are characterized by hyperandrogenemia, anovulation, and metabolic dysfunction. Hypothalamus–pituitary–ovary ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
For more information about INDIGO's GLP-1R, GIPR, and Glucagon Receptor Reporter Assays and other products and services, visit ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals. We sell different ...
DD01 is a liver-targeted, long-acting, dual GLP-1/glucagon receptor agonist previously shown to rapidly resolve hepatic steatosis, improve glycemic control, and reduce body weight in subjects with ...
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
glucagon-like peptide-1 (GLP-1), and glucagon receptors — experienced the greatest weight loss reductions among the agents studied. Data derived from; Moiz A, et al. Ann Intern Med. 2024 ...
GLP-1 receptor agonists stimulate the body to release insulin after eating. They also decrease glucagon release—preventing the body from mobilizing extra sugars—and slow stomach emptying.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results